Disease, MRI, PET Scan and Radiopharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Disease

MRI

PET Scan

Radiopharmaceuticals

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. Results demonstrated high detection rates (% positive PET scans) even at low PSA levels.

Diagnostic

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging

Unlocking the potential of imaging in Alzheimer’s disease care

AuntMinnie

JANUARY 19, 2024

more than 6 million Americans have Alzheimer's disease, a debilitating and far-reaching disease that accounts for 60% to 80% of dementia cases, and by 2050, this number is projected to rise to nearly 13 million, according to Alzheimer’s Disease International. The disease affects memory, thinking, and behavior. In the U.S.,

Disease

Disease Medicare Imaging PET Scan

Diagnostic Imaging Brief

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer

Unlocking the potential of imaging in Alzheimer’s disease care

Stay Connected